The CC-1065 molecule consists of 3 substituted benzodipyrrole moieties linked by amide bonds.
The "A" subunit has a cyclopropyl ring containing the only asymmetric carbons in the molecule.
While only the relative configuration of these carbons is available from X-ray data, the absolute configuration has been inferred as 3bR, 4aS by using DNA as a chiral reagent (vide infra)10). The "B"
and "C" subunits are identical benzodipyrrole moieties. CC-1065 has a right handed twist along its length, due to the out-of-plane distortion of the amide groups between each subunit6). The physicochemical properties of CC-1065 have been described3), and the tentative 13C NMR assignments have been proposed3,6) with revisions for the "A" subunit10). A comprehensive account of the 1H and 13C NMR assignments of CC-1065 and its acetic acid degradation product (3) will be presented in due course (SCAHIILL, T. A.: Unpublished results). Both the remarkable potency of CC-1065 and its unique structure make this drug molecule an attractive target for synthesis. The development of synthetic methodology is of course a prerequisite for the production of analogs of CC-1065. Synthetic analogs of CC-1065 will be particularly important in attempts to determine the molecular basis for the potency of CC-1065 and also to provide possible means to circumvent the hepatotoxicity of CC-106512) while attempting to retain the antitumor activity.
Synthesis of the "A" Subunit
The "A" subunit containing the alkylating cyclopropane ring perhaps presents the greatest challenge to the synthetic chemist. Several synthetic strategies have been described which lead to the moiety. WIERENGAl3) was the first to publish a pathway in which 4-chloro-3-nitroanisole (4) was converted in a regiospecific synthesis to the 6-hydroxyindoline (5). The aromatic ring of 5 was then nitrated and reduced to the amine to direct the regiospecific introduction of the 8-methylindolic moiety of 6. Through an intramolecular para alkylation reaction 6 was converted to cyclopropylspirocyclohexadienone (7), the "A" subunit of CC-1065.
MAGNUS and GALLAGHERI") have published a synthesis using the 3,3-bipyrrole (8) which was produced by sequential conjugate addition of p-tolylsulfonylmethyl isocyanide to ethyl sorbate. The 3,3-bipyrrole was then converted through a series of reactions into the acid chloride (9) which was immediately treated with SnCl4 -CH2Cl2 at -78°C to give the tricyclic phenol (10) . Selective reduction of 10 leads to the formation of the alcohol (11) which was converted by the intramolecular MITSU-NOBU reaction into the cyclopropylspirocyclo-hexadienone (12), the "A" subunit of CC-1065.
Most recently, KRAUS et al. 15 ) reacted the diene (13) regioselectively with 2-acetoxypento-l,3-diene, in a DIELS-ALDER reaction, to produce 14. Necessary protecting group shuffling, ozonolysis and cyclization afforded 15 which was converted to 12 in an overall yield of 5 % from 13.
Another interesting attempt has been made to synthesize the "A" subunit of CC-1065 by SUNDBERG and NISfficudH116), utilized an intramolecular carbenoid photoaddition route which gave cyclopropane-6-spiroindol-7-one but not the cyclopropane-4-spiroindol-7-one of CC-1065.
Synthesis of the "B" and "C" Subunits
At least five synthetic strategies leading to the identical "B" and "C" subunits of CC-1065 have been developed. Japanese workers in 1979 synthesized PDE-I17), which is similar in structure to the "B" and "C" subunits of CC -1065 by converting 7-hydroxy-6-methoxy-indole (16) into 7-benzyloxy-1-carbamoyl-2,3-dihydro-6-methoxy-5-nitro indole (17) . The nitro group of 17 was then reduced and converted into the hydrazone (18) . The hydrazone was converted through FISHER cyclization followed by deesterification to 19, the "B" and "C" subunits of CC-1065. (20) in seven steps with a 29% overall yield from 13, utilizing a synthetic route similar to the one they used to synthesize 12 reported before.
BOGER and COLEMAN19) have reported a synthetic pathway in which an intramolecular DIELS-ALDER reaction of alkyne 1,2-diazine (21) gave the tert-butyldimethylsilyl-protected indoline (22) . This was then deprotected and oxidized to the aldehyde (23) which was condensed with methylazidoacetate followed by mild thermolysis to give N-carbomethoxy-5-carbomethoxypyrrolo(3,2e)indoline (24) .
This strategy is now being applied toward the synthesis of the subunits of CC-1065.
RAWAL and CAVA20) have developed a photochemical strategy leading towards the synthesis of CC-1065 and its analogues. The trimethylammonium iodide was converted to the phosphonium salt (25) and condensed with ethyl N-benzyl-5-formylpyrrole-2-carboxylate (26) through a WITTIG olefination reaction to give the light sensitive olefin (27) . Oxidative photocyclization of 27 followed by a mild reduction gave the dideoxy-analog (28) of the CC-1065 "B" and "C" subunits. This procedure has been used to synthesize PDE-type units which contain other hetero-atoms and is currently being applied toward the synthesis of CC-1065 subunits.
HALAZY and MAGNUS21,22) have recently reported their strategy for the synthesis of the key features of the "B" and "C" subunits. The bipyrrole (29) was made by standard methods14) and treated with oxalyl chloride to give the o-quinone (30) . The reduction of 30 with P(OCH3)3 followed by hydrolysis gave the phenolic phosphate ester (31) . Cyclic oxaphospholene was used for the O-methylation of 31 followed by alkaline conditions for the removal of the phosphate ester. The phenol was reprotected and the tert-butyl ester removed to give the acid (32) . The acid was decarboxylated, the unsubstituted double bond was reduced, and the amine protected to give the diacetate (33) .
SUNDBERG and PEARCE23' have most recently described their strategy for the synthesis of several compounds related to the "B" and "C" subunits of CC-1065. 
Properties of CC-1065-modified DNA
The binding of CC-1065 to DNA polymers has been found to result in profound stabilization of the double helix. This is illustrated by the results of experiments examining the effects of drug binding on 1) DNA-helix melting temperature, 2) DNA susceptibility to S1 nuclease digestion, and 3) the ability of ethidium bromide to intercalate and unwind supercoiled DNA.
Results suggest that overstabilization of the DNA-helix may be important in the mechanism of action of CC-106525).
The effect of CC-1065 on the thermal melting transition of DNA has been studied25). The results In experiments carried out to determine the effect of CC-1065 binding on the sensitivity of DNA to digestion by S1 nuclease (which degrades single stranded DNA), it was determined that drug binding greatly inhibited the action of S1 nuclease25).
This was interpreted to mean that CC-1065 suppresses local, transient DNA strand separation ("DNA breathing") in much the same way as was observed for the inhibition of thermally-induced DNA strand separation (see earlier discussion). affected to a lesser degree and protein synthesis was the least affected. The inhibition of DNA synthesis by CC-1065 was examined in vitro using DNA polymerase-a24). Inhibition of DNA polymerase-a activity by CC-1065 was attributed to the ability of the drug to interact with the DNA template.
The profound effects of CC-1065 on DNA synthesis are somewhat surprising when considered in relation to studies on the cell cycle specificity of the drug where despite the potent inhibitory effects of CC-1065 on DNA synthesis, it was observed that S phase cells are the most resistant to the lethal effects of the drug26). Cells in G2 and M phase were the most sensitive. It was speculated that the absence of a nuclear membrane in mitotic cells might allow more drug to reach the DNA 26). The effects of CC-1065 on the progression of the cell cycle26) revealed that CC-1065 blocked cells in G2+
M. No effect was noted in the transitions of M to G1 or G1 to S. Even though CC-1065 had a potent inhibitory effect on DNA synthesis, cells were able to pass slowly (50% of control rate) through S 2) As measured by difference CD, CC-1065 was able to react with bacteriophage T4 DNA (65 glucosylated in the major groove) to almost the same extent (Table 1) as with calf thymus DNA (no major groove modifications)25). This result indicated that CC-1065 was unlikely to bind in the major groove of DNA.
3) Results of alkylation inhibition studies") demonstrated that the binding of CC-1065 to DNA
produced an inhibition of alkylation by methylnitrosourea and ethylnitrosourea at sites in the minor groove. No such inhibition of alkylation of sites in the major groove was detected. Similar results were obtained in experiments using CC-1065 to inhibit alkylation by methyl methane sulfonate25).
While the results of these studies do not rule out the possibility that CC-1065 may interact to a small degree with the major groove, the evidence overwhelmingly points to the minor groove as the predominant (if not the exclusive) site of CC-1065 binding by DNA.
CC-1065 Binds Covalently to N3 of Adenine
Initial results from binding experiments using synthetic DNA polymers (Table 1) (Fig. 4) . The identity of this 5'-phosphate group was recently confirmed in experiments33) using DEAE-cellulose chromatography34) on DNA fragments released from treatment of CC-1065-poly(dA. dT) adducts following successive thermal and AP-endonuclease II treatment. The inability to label the 3'-terminus of the thermal cleavage product by Escherichia coli DNA polymerase I suggests that this 3'-terminus is a modified deoxyribose33). These results are consistent with a single thermally-induced n-elimination occurring on the 3'-side of the adenine to which CC-1065 is covalently bound (Fig. 4) .
Sequence Specificity of CC-1065
The observation that CC-1065-DNA adducts were associated with the production of singlestrand breaks in DNA at elevated temperatures224) led to the formulation of a strategy to examine the DNA sequence specificity of CC-106530). In these experiments, aliquots of singly 32P end-labeled DNA restriction fragments were subjected either to Maxam-Gilbert sequencing reactions32) or to incubation with various doses of CC-1065 followed by thermal treatment. In all, DNA restriction fragments consisting of over 1,000 bases were examined for CC-1065 binding sequences. A compilation of the sequences of these and other CC-1065 binding sites revealed the DNA sequence specificity of CC-1065. Two consensus sequences, 5'-PuNTTA* and 5'-AAAAA*, were identified in which CC-1065 bound covalently to A*30)
Characterization of a Defined CC-1065-oligodeoxynucleotide Adduct
The previously described sequence specificity studies provided insight into a DNA sequence (5'-CGGAGTTAGGGGCG) which should bind one molecule of CC-1065 in an unambiguous manner. This sequence, which contains the CC-1065 adenine binding site within the sequence 5'-TTA, was chemically synthesized together with the complementary strand35. CC-1065 reacted with the oligoduplex to produce an adduct that maintained the B-DNA form and had a final CD spectrum similar to those of the CC-1065 complexes formed with calf thymus DNA. The above 14mer was 5' end-labeled with 32P, annealed with its complementary strand, reacted with CC-1065 and heated.
Drug-mediated strand breakage was evaluated on a Maxam-Gilbert sequencing gel. A single DNA strand break occurred in the labeled strands to produce a DNA fragment that migrated as an 8.5mer; subsequent piperidine treatment produced a DNA fragment that migrated as a 7mer. These were the sizes expected from the known binding of CC-1065 at adenine in 5'-TTA of the 14mer sequence35).
Orientation of CC-1065 in the Minor Groove of DNA and Absolute Stereochemistry of the Cyclopropane Ring of CC-1065 CPK models of the CC-1065-(N3-adenine)-DNA adduct predict that the drug molecule should cover about 5 base pairs36. However, since only the relative stereochemistry at C-3b and C-4a is known from X-ray crystallography6), the polarity of the drug molecule in the minor groove in reference to the covalent binding site could not be predicted. The sequence specificity data confirm the CPK model prediction that CC-1065 should span about 5 base pairs, since this is the extent of the DNA sequence specificity (i.e., 5'-PuNTTA* and 5'-AAAAA* where the drug binds covalently to A*). in murine models were fairly limited3). Confirmed activity meeting the NCI "good-activity" criterion (DN-2) was noted only against the ip-implanted B16 melanoma. Confirmed activity meeting the NCI "minimum-activity" criterion (MC-1) was observed against the sc-implanted CD8F1 mammary carcinoma, the ip-implanted colon 26 carcinoma, ip P388 leukemia, and ip L1210 leukemia. CC-1065 given ip was inactive upon initial or confirmation testing against the sc CX-1 colon xenograft, sc colon 38 carcinoma, sc LX-1 lung xenograft, iv Lewis lung carcinoma, and the sc MX-1 breast xenograft. Thus CC-1065 had significant activity only in models where both tumor cells and drug were injected ip.
Increases in life span (ILS) of 81 and 59 % were attained in two experiments with daily x 9 ip treatment of mice bearing ip-implanted B16 melanoma. Optimal doses were 33 and 12.5 µg/kg/day, respectively. No long-term survivors were observed. Against the ip P388 leukemia, ILS's of 111 and 70% and no long-term survivors were noted at optimal doses of 30 and 180 µg/kg/day, ip, days 1, 5, 9. In schedule-dependency testing in mice bearing ip-implanted P388, the days 1, 5, 9 schedule was marginally more active than the day 1 only schedule. ILS's were somewhat lower with days 1 -9 treatment.
BHUYAN et al. tested CC-1065 using the in vitro human tumor cloning assay35). With 1 hour exposure to 0.1 ng/ml, a 70% decrease in tumor-colony forming units (T-CFU) compared to control plates was noted in 1/9 tumors from lung cancer patients, 1/2 pancreatic tumors, 1/1 small bowel tumor, and 1 /2 adenocarcinomas of unknown origin. Using >50% decrease as the criterion, CC-1065 was active against tumor explants from patients with cancer of the breast (3/9), ovary (2/8), pancreas (1/2), multiple myeloma (2/2), stomach (1/1), testis (1/1), small bowel (1/1), and adenocarcinoma of unknown origin (1/2). CC-1065 was not significantly active (<50% decrease in T-CFU) against tumor explants from one or more patients with melanoma, leukemia, esophageal cancer, nonHodgkin's lymphoma, colon cancer or sarcoma.
Toxicology
Administration of CC-1065 to non-tumor-bearing mice revealed an unusual delayed form of hepatotoxicity occurring at the doses which prolonged life in tumor-bearing mice12). Toxic deaths were delayed ca. 50 days after a single iv dose of 12.5 µg/kg and as much as 70 days after 10,ug/kg was given ip. Mouse intravenous LD50's were 9µg/kg, single dose, and 0.3 ,ug/kg/day, five daily doses. Intraperitoneal LD50's were variable between experiments, ranging from 0.53 ~ 6.90 µg/kg, single dose. Mice treated with high doses iv died within 12 days with frank hepatic necrosis, whereas delayed deaths at lower doses were associated with ultrastructural changes in hepatic mitochondria. This suggested that separate mechanisms of hepatotoxicity were operative at high and low dose ranges.
In lower dose ip-treated mice (moribund at day 30), extensive visceral adhesions involving the alimentary canal and the liver were observed. In this respect, CC-1065 appeared to be similar to VM-26 and various antileukemic phthalanilides, which caused a chemical form of peritonitis when administered ip39, 40) Attempts to prevent the delayed toxicity of CC-1065 in the mouse by treatment with WR-2721, N-acetylcysteine, and agents inducing cytochrome P-450 metabolism were unsuccessful. No effect on LD50's or times of death were noted. Intravenous administration of lethal doses of CC-1065 to rabbits resulted in a pattern of toxicity similar to that seen in mice. Some deaths were delayed beyond 20 days and gross and microscopic evidence of liver damage was observed.
Conclusions CC-1065 is a structurally and biosynthetically unique antitumor antibiotic that is believed to exert its potent antitumor activity by binding covalently to DNA through N3 of adenine. Although the spectrum and degree of antitumor efficacy in murine models is fairly limited, CC-1065 is one of the most potent compounds on a molar basis to be evaluated for antitumor activity. CC-1065 causes an unusual delayed form of hepatotoxicity at doses which prolong life in tumor-bearing animals.
Several synthetic strategies have been developed to produce the alkylating "A" subunit of CC-1065, which is required for antitumor activity. Based upon one of these synthetic schemes"), analogs of CC-1065 have recently been made available for antitumor and cytotoxicity evaluations41,42). These analogs, which retain the "A" subunit but have modified "B" and "C" subunits, maintain the high level of biological potency in antitumor models while having reduced hepatotoxicity.
CC-1065 is one of a number of potent antitumor antibiotics which bind covalently in the minor groove of DNA without major distortion of the helix. The anthramycins are the other major group of compounds which bind covalently to DNA through a minor groove bindings site, in this case N2 of guanine2I.20). Whether the potent biological effects of drugs that bind covalently in the minor groove are mediated through a common mechanism or not is unknown. We suggest that a common feature of CC-1065 and the anthramycins is the ability to form DNA adducts which may prove difficult to repair because of the nondistortive and stabilizing effects of drug binding.
The DNA adduct formed with CC-1065 is comparatively well characterized in a three dimensional sense. The 4~ 5 base pair sequence specificity can be rationalized by the computer-generated stereodiagrams of the CC-1065-DNA adduct. Our knowledge of the sequence specificity of CC-1065 has allowed us to synthesize oligodeoxynucleotides of defined sequence which form unique adducts with CC-1065, Our present work is concerned with the preparation of defined CC-1065-adducts in much longer pieces of DNA for structural and biochemical studies.
